a b s t r a c t Tuberculosis (TB) remains one of the most important infectious diseases of man and animals, and the only available vaccine (BCG) requires urgent replacement or improvement. To facilitate this, the protective mechanisms induced by BCG require further understanding. As a live attenuated vaccine, persistence of BCG bacilli in the host may be a crucial mechanism.
Introduction
Tuberculosis (TB) caused by infection with Mycobacterium tuberculosis (M. tb) or Mycobacterium bovis (M. bovis) remains one of the most important infectious diseases of man and animals, respectively; inflicting a huge cost in both health, welfare and financial terms [1] .
At present the only vaccine against TB is M. bovis bacille Calmette-Guérin (BCG), which demonstrates variable efficacy in humans and cattle [2, 3] . In particular, BCG appears effective in childhood, but not in adolescents and adults [4] . Despite this performance, BCG remains the most widely used human vaccine, and due to its partial efficacy and proven safety record, is unlikely to be withdrawn and remains the benchmark to improve upon.
It is clear that optimal protection against TB requires CD4 T cells, as well as the effector cytokines IFN-␥ and TNF-␣ (reviewed in [5] ).
However, as other studies demonstrate; CD4 T cell derived IFN-␥ is not an exclusive component of vaccine-mediated immunity [6] and identification of other critical components of protection remains elusive.
To compound our incomplete knowledge, the study of BCG induced immune memory has also proven difficult. The chronic nature of TB infection, lack of sterilising immunity, and transient protective window, all contribute to complicate the characterisation of vaccine-specific T cell memory.
Memory T cells exist in a number of subsets. Classically, these are understood to be partitioned into effector memory (T EM ) and central memory (T CM ) categories [7] ; but recent evidence argues for a complex functional diversity within these two broad categories in vivo (reviewed in [8] ).
There has been an intensive effort to characterise T cell memory induced by BCG immunization in both animal models [9] [10] [11] [12] [13] [14] and humans [15] [16] [17] . Given its variable efficacy, it is of critical importance to understand the mechanisms underlying its protective capacity, if improved vaccines or vaccination strategies are to be progressed. The majority of these studies report BCG to induce a predominant CD4 T EM response, defined by CD62L lo expression, often associated with cytokine multifunctionality [9, 16, 18] ; but few identify BCG-specific CD62L hi or CCR7 hi CD4 T CM responses [19] [20] [21] [22] . We recently reported CD4 T EM cells to persist 18 months following BCG immunization [9] , and consistently, observe no defined contraction of immune responses following immunization.
Given the potential of BCG to persist in the immuno-competent host [23] [24] [25] [26] [27] , combined with the absence of immune contraction; we hypothesised whether these CD4 T EM cells represent: (a) genuine long-lived high frequency memory cells, or alternately; (b) result from continual priming by persistent BCG bacilli.
Therefore, we sought to investigate the persistence of live BCG long after immunization and the influence of this on immune responses and protection against M. bovis challenge, in a mouse model [28] .
We report here that live BCG vaccine persisted for the 16 month period of study and that clearance of these bacilli by antibiotic treatment resulted in abrogation of the BCG-specific CD4 T cell population; but protective immunity was only reduced by ∼50%. Thus, we propose the existence of two separate additive mechanisms of protection induced by BCG; one dependent on, and one independent of persistent BCG and associated T EM population. These data may have crucial implications on the rational generation of replacement or adjunct TB vaccines, and the interpretation of BCG induced immunity in animal models.
Materials and methods

Ethics
All animal work was carried out in accordance with the UK Animal (Scientific Procedures) Act 1986; under appropriate licences. The study protocol was approved by the AHVLA Animal Use Ethics Committee (UK PCD number 70/6905).
Animals
Female BALB/c mice were obtained from SPF facilities at Charles River UK Ltd and used at 8 weeks of age. All animals were housed in appropriate BSL3 containment facilities at AHVLA.
Mycobacteria
The vaccination strain was the human vaccine M. bovis BCG Danish 1331, prepared as per manufacturer's instructions (SSI, Denmark).
Mycobacterium bovis isolate AF2122/97 was used for all challenge experiments as previously described [9] .
Mycobacterial antigens
A pool of 7 recombinant mycobacterial proteins (Rv1886c, Rv0251, Rv0287, Rv0288, Rv3019c, Rv3763, Rv3804c), were used for all stimulations as previously described [9] . All proteins were extensively dialyzed and re-suspended in physiological buffer (HBSS) before use.
Immunization, mycobacterial enumeration and challenge
Mice were immunized with a single intradermal injection (50 l) containing 2 × 10 5 CFU of BCG, or sham control (HBSS) in the base of the tail. For enumeration of viable BCG, the spleen, lung, liver and the pooled LNs draining the site of immunization [29] (inguinal, iliac and axillary) were aseptically removed, homogenized and plated in their entirety onto modified Middlebrook 7H11 agar (Difco TM ) plates [30] . CFU were enumerated twelve weeks after incubation at 37 • C. Limit of detection (LOD) was 2 CFU. A sample of colonies at 16 months was verified as BCG by molecular typing [31] .
Additionally, thirty weeks following immunization, mice were challenged intranasally with ∼600 CFU of M. bovis as previously described [28] . Bacterial loads in spleen and lungs were enumerated four weeks after challenge as previously described [28] .
Antibiotic clearance of BCG bacilli (BCG abbreviated)
Drinking water containing antibiotics (100 g/ml ethambutol, 200 g/ml isoniazid and 100 g/ml rifampicin) (all Sigma, UK), was provided ad libitum, replenished twice weekly for the period of treatment. Placebo comprised D.H 2 O containing the same volume of solvent (DMSO) used to prepare antibiotics.
Cell isolations and stimulations
On euthanasia, spleen, lung and LNs (inguinal, iliac, axillary, brachial, cervical and popliteal) were aseptically removed and spleen and interstitial lung cells prepared as previously described [9] . LN cells were prepared as spleen cells. Following washing (300 g/8 min), all cells were re-suspended at 5 × 10 6 ml −1 for assays. Cells were cultured with the specific protein cocktail as described, each antigen at final concentration of 2 g/ml for all assays.
ELISPOT
Cells were incubated with antigen and the frequency of antigenspecific IFN-␥ secretors detected by ELISPOT (Mabtech, Sweden), as previously described [9] .
Flow cytometry
For intracellular staining (ICS), cells isolated from spleen or lungs were stimulated with antigen pool and anti-CD28 (BD Biosciences) as previously described [9] . They were surface stained with CD4-APC-H7, CD19-PE-CF594, CD11b-PE-CF594 (all BD Bioscience), CD44-eFluor 450, CD62L -PE or -PerCP-Cy5.5, CD27-PE and LIVE/DEAD ® Fixable Yellow Dead Cell Stain ('YeViD', Invitrogen). Subsequently, cells were washed, fixed and permeabilised and stained for ICS with IFN-␥-APC (BD Bioscience), IL-2-PE-Cy7 and TNF-␣-FITC as previously described [9] .
For MHC class II-peptide tetramer staining, RBC were removed (spleen samples only) using RBC lysis buffer (eBioscience, USA). Cells were stained (45 min/37 • C/5% CO 2 ) in culture media with Rv0288 (TB10.4) peptide: MHCII I-A( d ) (SSTHEANTMAMMARDT) tetramer-complex, labeled with APC; or I-A( d ) negative control (PVSKMRMATPLLMQA) tetramer-APC (both provided by NIH MHC Tetramer Core Facility, USA). Following washing, they were stained (15 min/4 • C) in staining buffer with CD4-APC-H7, CD44-FITC, CD62L-PerCP-Cy5.5, and YeViD, washed and fixed with Cytofix.
All antibody conjugates were purchased from eBioscience except where stated. Data were acquired using a Beckman Coulter CyAn ADP (retrofitted with a 562/40 bandpass filter in the second channel of the violet laser) and analyzed on Summit v4.3 (Beckman Coulter, USA) or Flowjo v7.6.5 (Tree Star, USA) software. All analyses were gated on a minimum of 100,000 live lymphocytes.
Statistical analyses
All data were analyzed with GraphPad Prism 5 software (GraphPad, USA) using un-paired student's two-sided t-test (2 treatment groups) or one-or two-way ANOVA with Bonferroni post-test (3 treatment groups). Mycobacterial counts were log 10 transformed before comparison. A Two-tailed correlation analysis was used to obtain coefficient of determination (r 2 ) from the Pearson correlation coefficient (r). Differences with a p value <0.05 were considered significant and denoted with * , <0.01 with ** and <0.001 with *** .
Results
BCG-bacilli and -specific IFN-responses persist for at least 16 months in vaccinated mice and demonstrate a defined correlation
To establish the long-term persistence of viable BCG bacilli, groups of mice were immunized at week 0 with a standard dose (2 × 10 5 CFU) of the licensed human vaccine BCG Danish 1331. At sequential monthly time-points, the BCG burden of individual mice was determined in pooled draining lymph nodes (d.LNs), spleen and lungs; plating the entire organs/tissues to maximise detection. Fig. 1A demonstrates that viable BCG bacilli were cultured from the d.LNs throughout the experimental duration of 16 months. The burden was highest and most consistent at 6 weeks post immunization (p.i.) at 3.0 log 10 CFU (±0.5), decreasing to 2.4 log 10 CFU (±0.5) at 16 months p.i.
BCG were cultured from the majority of spleen samples, although with large replicate variability. CFU counts increased from 1.7 log 10 CFU (±1.7) at 6 weeks p.i. to 2.3 log 10 CFU (±2.3) at 17 weeks p.i., decreasing to 0.0 log 10 CFU (±2.0) by 16 months p.i. Culture of BCG from the lungs was sporadic and only possible in 1 or 2 replicates at each time point up to 22 weeks p.i., after which it was undetected.
Given the established importance of IFN-␥ producing CD4 T cells in protection against TB, the frequency of BCG-specific IFN-␥ secretors in the spleen was evaluated by ex vivo ELISPOT using defined protein cocktail at defined time-points following BCG immunization. Fig. 1B shows that whilst IFN-␥ secreting cell frequency was maximal at 6 weeks p.i. (1197 SFU/million cells) and declined thereafter; substantial frequencies of IFN-␥ secreting cells (478 SFU/million cells) were present 16 months p.i., as previously described [9] .
Regression analyses between the mean spleen IFN-␥ ELISPOT frequency and the mean bacterial burden in d.LNs showed a statistically significant correlation, demonstrating a clear link between antigen load (from the most reliable tissue indicator) and IFN-␥ responses circulating through the spleen (Fig. 1C) .
Antibiotic treatment abrogates BCG persistence and specific IFN-effector response
To establish the minimum treatment regimen to clear persistent bacilli after BCG immunization, groups of mice were immunized with BCG for 6 weeks (previously shown to induce protection) [9, 28] . They were then given a 0, 1, 2 or 3 month course of antibiotic treatment (subsequently termed BCG abbreviated) of ethambutol, isoniazid and rifampicin via drinking water. Mice were returned to normal water for a further two weeks following the cessation of treatment, to flush any residual in vivo antibiotics inhibiting bacterial culture.
At the end of each treatment regimen, bacterial burden in the individual organs/tissues was determined as described previously; with the inclusion of the liver as an additional potential reservoir of bacilli. Fig. 2A shows that 1 month of treatment was sufficient to clear residual bacilli from the spleen; but a further 2 months of treatment were required to consistently clear persistent BCG from the d.LNs in all animals. The pre-treatment burdens observed in both the spleen and d.LNs were equivalent to previous experiments ( Fig. 2A cf. Fig. 1A ). BCG in lungs and liver were undetectable in this experiment.
As further experiments were critically dependant on consistent efficacy of treatment, a further experiment included vaccinated mice given an additional 3 months rest after cessation of 3 months treatment. In contrast to immunised, untreated mice (which had a burden of 2.7 log 10 CFU (±0.6) in the d.LNs ∼7.5 months p.i.), no viable BCG were detected in the treatment group (Fig. 2B) confirming the efficacy of antimicrobial treatment.
To evaluate the effect of persistent BCG bacilli on specific IFN-␥ responses, groups of mice were immunized with BCG or placebo control for 6 weeks, prior to treatment with antibiotics or placebo for 3 months. To ensure that: (a) analyses were not influenced by short-lived effector T cell responses; and (b) BCG bacilli were effectively cleared, animals were rested for 3 months after treatment. The frequency of BCG-specific IFN-␥ secreting cells in the spleen was then evaluated by ex vivo ELISPOT stimulated with the defined protein cocktail. Fig. 2C shows that the significant IFN-␥ response induced by BCG immunization (613 SFU/million cells) was completely abrogated in BCG abbreviated animals (p < 0.001). These data clearly demonstrate that, the persisting IFN-␥ responses observed in BCG immunized animals were due to persistent BCG bacilli, rather than long-term memory.
The presence of BCG-specific multifunctional CD4 T EM cells is dependent upon the presence of live BCG bacilli
To further investigate whether this ablation of the IFN-␥ responses (ELISPOT) in BCG abbreviated mice was specific to CD4 T cells and of what memory phenotype, the CD4 T cell responses specific to BCG in spleen and lung were assessed by intracellular cytokine staining (ICS) after stimulation with defined protein cocktail (Fig. 3) . Fig. 3A shows BCG immunization induces significant populations of multifunctional CD4 T cells (IFN-␥ + /IL-2 + /TNF-␣ + , IFN-␥ + /TNF-␣ + and IL-2 + /TNF-␣ + ), in both spleen and lung-derived cells, with frequencies considerably higher in the lungs as reported previously [9] . ICS performed on d.LN samples of BCG immunized mice in previous experiments were unable to detect significant populations of cytokine producing cells (data not shown), and so were not performed here. Consistently, no BCG-specific CD8 responses were detectable in any of these, or previously reported experiments [9] .
Further, these data demonstrate the clearance of persistent BCG bacilli significantly ablates (p < 0.001) the presence of all cytokine producing CD4 T cells in both the spleen and lungs (Fig. 3A) . Consistent with previous data [9] these multifunctional CD4 T cells consist entirely of CD44 hi CD62L lo cells indicative of a T EM phenotype (spleen-99.3%; lung-99.6% of total cytokine + cells) as shown in Figs. 3B (representative plots of spleen and lung CD4 T cells) and S1 (gating strategy).
We considered that the absence of a measurable T CM (CD62L hi ) response may be due to the effector cell focus of the assays thus used. We therefore used a class II MHC -TB10.4 (73-88 a.a.) peptide-tetramer complex to detect the total CD4 T cell population specific to this immunodominant antigen in spleens of vaccinated or BCG abbreviated mice, (Figs. 3C and D). As shown in Fig. 3C , 0.23% of total spleen CD4 T cells were CD62L lo Tet + ; reduced to 0.03% CD62L lo Tet + following BCG abbreviation (Figs 3C and D) . There were no vaccine-specific CD62L hi Tet + CD4 T cells in the spleen (Fig. 3C) 
or LNs (data not shown). Tetramer analysis of lung cells was not performed due to insufficient yields.
These data demonstrate both systemic and mucosal CD4 T cell responses to BCG vaccination are dependent on the persistence of live bacilli, and that these responses are dominated by multifunctional CD4 T EM cells, with no detectable CD4 T CM cells.
Protection is optimal in the presence of, but not dependant on, persistent BCG bacilli
To determine the effect of these persistent viable vaccine bacilli upon BCG-induced protection; equivalent groups of mice were subjected to this antibiotic treatment regimen, prior to intranasal challenge with M. bovis for 4 weeks. As described in Fig. 4 , both BCG and BCG abbreviated immunized mice exhibited significant protection compared to placebo controls in both the spleen (Fig. 4A ): BCG-protection 1.6 log 10 (p < 0.001); BCG-abbreviated-0.8 (p < 0.001), and the lungs (Fig. 4B ): BCG-protection 1.7 log 10 (p < 0.001); BCGabbreviated-0.7 (p < 0.01). Protection in BCG-abbreviated mice, however, was significantly less compared to untreated BCG vaccinates (spleen 52% reduction cf. untreated, p < 0.01; lungs 40% cf. untreated, p < 0.001).
These data demonstrate that whilst BCG induced protection is optimal when persistent bacilli are present; significant protection is maintained after clearance of these bacilli.
Discussion
As BCG remains the benchmark to improve upon, it is critical to understand the mechanisms underlying its protective efficacy if improved vaccines or vaccination strategies for TB are to progress. Primary to this aim must be further investigation on the establishment and maintenance of BCG-induced memory.
We report that intradermal immunization with a relatively low dose of BCG (2 × 10 5 CFU) results in a persistent 'infection', with viable vaccine bacilli present in the secondary lymphoid organs (SLO) for up to 66 weeks. Further, we demonstrate a direct relationship between the BCG burden and the frequency of IFN-␥ responses. We establish that clearance of these bacilli requires sustained antibiotic treatment, and abrogates the cytokine producing vaccine-specific CD4 T cells derived from the spleen and the lungs. Strikingly, although substantially decreased, significant pulmonary and systemic protection was still present following clearance of bacilli. Together these data suggest BCG may induce two mechanisms of immunity: (i) dependant on the presence of viable bacilli and associated T EM ; and (ii) a further mechanism, independent of persisting bacilli and T EM . The exact details of the latter mechanism are yet to be elucidated, and are the subject of current investigation.
The question of BCG persistence has been noted in previous studies in mice [24, 25, 27, [32] [33] [34] [35] , other animal models [23, 26] and humans [36, 37] . In a similar study using C57BL/6 mice and M. tb challenge [27] , spleen protection was reduced by 75%, but in contrast lung immunity was unaffected. This disparity with our study could be due to: mouse strain, challenge organism, incomplete BCG bacilli clearance, or the shorter duration between chemotherapy and challenge.
To date, however, no relationship between BCG persistence and the predominance of CD4 T EM responses has been reported [9, 16, 18, 38] . Our data indicate a clear link between BCG antigen load and T cell responses, which as demonstrated here and previously, are multifunctional (IFN-␥ + /IL-2 + /TNF-␣ + , IFN-␥ + /TNF-␣ + and IL-2 + /TNF-␣ + ) CD62L l• CD4 T cells which we consider T EM [9] . We also demonstrate that antigen-specific IFN-␥ could used as a direct surrogate of viable bacilli (with the caveat of appropriate antigen stimulation).
We cannot rule out that our antibiotic regimen did not completely eliminate the persistent BCG without performing subsequent immunosuppression [39] , which was beyond the scope of our study. However, our data clearly demonstrate reproducible elimination to a point that no BCG baciili and antigen-specific cells could be detected after 3 months of 'rest'. Therefore, we consider this sufficient BCG clearance for the objectives of this study.
We define these IFN-␥ + /IL-2 + /TNF-␣ + triple-or bi-functional cells as CD4 T EM based on CD62L lo CCR7 − expression [9] . As CD62L can be cleaved by metalloproteases, we previously conducted studies using the inhibitor TAPI-2 [40] to demonstrate that identification of stimulated-responder cells as CD62L lo was not due to non-specific mechanisms of CD62L down-regulation (data not shown). We have also confirmed this by sorting CD62L lo/hi cells prior to functional assay (Kaveh & Hogarth, unpublished data) .
Following BCG clearance, this absence of CD4 T EM cells, and indeed any detectable antigen-specific IFN-␥ responses (ELISPOT) or cells expressing a T cell receptor (TCR) specific to an immunodominant antigen; indicates that all detectable responses result from continual priming by BCG bacilli, as has been reported during chronic Salmonella infection [41] , and that they are relatively shortlived. Whilst determination of specific CD4 T EM cell longevity was beyond the scope of this study; they were absent at four months following last detection of viable bacilli, indicating a lifespan of <four months; conforming to the hypothesis that T EM cells are responsible for intermediate, rather than long-term memory [42] . Interestingly, our previous data show lung T EM responses were sustained at 12 months following BCG immunization. [9] , at which point we show here there are no detectable bacilli in the lung, indicating traffic from a site of active priming such as the SLO; according with reports that responses to mycobacteria are initiated in the LN [43, 44] .
Despite their short-lived nature, CD4 T EM cells appear to make a significant contribution to protective immunity, as the reduction in bacterial burden was reduced by up to 60% in their absence. CD4 T EM have been reported as important mediators of protection in M. tuberculosis [45] malaria [46] and Leishmania [38] , among other infections. We acknowledge, however, that a direct protective, rather than associative role of these cells remains to be shown; but at present, the lack of technologies to allow the sorting of live T cells based on cytokine production, preclude the T EM adoptive transfer experiments required to definitively demonstrate such a role.
It is intriguing to speculate whether at least a proportion of the protection afforded by BCG during childhood is due to persisting bacilli and associated T EM . There is evidence that BCG may persist for many years in humans [37, [47] [48] [49] [50] [51] [52] and together with the observed waning of immune responses to BCG through childhood [36] ; this may represent gradual clearance of bacilli and associated T cells.
Long-term memory, however, is considered dependent on the generation of T CM responses. At present, few reports directly identify an antigen-specific CD4 T CM cells induced in mice by BCG alone [19, 22] ; some describe T CM -like cells after clonal expansion induced by prime-boost vaccination, challenge or reinfection [14, 21, 53] . In humans, T CM may only appear after contraction of the BCG-specific T EM response [20] . This situation is confounded by our incomplete understanding of T CM cell phenotypes. Conflicting evidence is often published, and there is clearly substantial plasticity between memory T cell phenotypes (reviewed in [42, 54] ). Unequivocal identification of these cells is also complicated by the weak expression of characterisitic cells markers (e.g. CCR7) and their often mutual expression by the naïve T cell population.
ICS by flow cytometry is often used, but has a distinct effector bias relying immediate cytokine production, and so is unlikely optimal for T CM detection [55, 56] . To circumvent this, we performed class II-peptide tetramer staining, but were unable to detect any CD4 + CD62L hi antigen-spepcific T CM cells. Perhaps the paucity of reported T CM responses to vaccination is due to rarity of these cells, estimated at 0.025-0.0025% of total CD4 T cells [57] . The background responses of most assays in naïve mice (<0.05% CD4 T cells) may obscure such populations [57] . Indeed, recent studies have had to employ enrichment of tetramer + cells [58] , to allow detection of rare T CM cells in BCG vaccinates [19, 22] . Other in vitro expansion approaches, such as cultured ELISPOT [59] may also help to resolve this population.
Therefore, we cannot rule out the existence of undetected BCG-specific T CM . The existence of potential T CM cells has been demonstrated in adoptive-transfer experiments, where cells with a potential T CM phenotype (CD62L hi /CD45RB hi , but unknown for CCR7) conferred modest protection [12, 60] .
In the absence of a robust T CM response, other potential mechanisms of protection in BCG abbreviated mice may include alternate T cell subsets secreting cytokines not examined in this study (e.g. T H 17 [13] ), or undetected CD8 T cells, B cells or 'innate' cell activation and imprinting [61] .
Current models for assessing TB vaccines compare performance against the BCG 'gold standard', which likely include persistent bacilli and thus active T EM responses. This may account for the inability to improve upon BCG often reported [62] . A model where protection is assessed against only long-term memory, such as the abbreviation method used here, or other strategies to remove constant priming; may allow an enhanced 'window of protection' and subsequent identification of vaccines with potential for improved performance.
This report has implications for the interpretation of immunity in pre-clinical models, with predominant responses dependent on antigen persistence. Therefore, studies which include such persistent BCG, not only demand a vaccine candidate to outperform the 'gold standard' in the face of constantly primed T Effector and T EM responses; but also confound interpretation of the immunological analyses, with the dominant responses induced by live BCG undoubtedly obscuring the immune responses responsible for long-term memory-mediated protection. This underscores the importance of understanding the mechanisms of T cell memory.
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